Ribociclib (Ribociclib) launch time and price in China

Ribociclib (Ribociclib) is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, specifically used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. The drug was developed by the Swiss company Novartis and sold under the trade name Kisqali.

Ribociclib (Riboxiclib) has been on the market in China for 2023 years. Since its launch, Ribociclib has quickly become an important treatment option for patients with HR+/HER2- breast cancer and has been included in China's national medical insurance directory. This initiative greatly reduces the financial burden on patients, making this advanced treatment affordable for more patients.

In terms of price,the cost of Ribociclib has been significantly reduced after being included in medical insurance. Currently, in China, the market price of ribociclib (riboxil) is approximately 8,000 yuan per box. However, the specific payment amount will vary depending on the medical insurance policy and reimbursement ratio in the patient's location. For the most accurate pricing information and reimbursement rates, patients should consult their local hospital pharmacy or health insurance agency.

In addition to the domestic original drug, the Indian version of ribociclib (ribociclib) is also attracting attention in the market. The price of the Indian version of the original medicine is about 3,000 yuan, which is significantly lower than the domestic market price. Despite the significant price difference, the efficacy and ingredients of the Indian version of Ribociclib are consistent with those of the domestic original drug. India is known for its high-quality generic drug production, with strict production standards and quality control ensuring the safety and effectiveness of the drugs. Therefore, the Indian version of the originator drug provides an affordable alternative for patients who require long-term use of ribociclib.

Ribociclib prevents the cell cycle by inhibiting CDK4 and CDK6 G1progress, thereby inhibiting the proliferation of cancer cells. Clinical studies have shown that Ribociclib (Riboxiclib) combined with aromatase inhibitors (such as Letrozole) or other endocrine therapies (such as Fulvestrant) can significantly extend patients' progression-free survival (PFS) and improve their quality of life. Although the drug is highly effective, common side effects include neutropenia, elevated liver enzymes, nausea, fatigue, and hair loss. Therefore, patients need to regularly monitor blood routine, liver function and electrocardiogram when using ribociclib (ribociclib) to ensure safe medication.